SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-014350 to CURIS INC (CRIS)

CURIS INC
Date: Dec. 31, 2024 · CIK: 0001108205 · Accession: 0000000000-24-014350

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-284009

Date
December 31, 2024
Author
James E. Dentzer
Form
UPLOAD
Company
CURIS INC

Letter

December 31, 2024 James E. Dentzer President and Chief Executive Officer Curis, Inc. 128 Spring Street, Building C - Suite 500 Lexington, MA 02421 Re:Curis, Inc. Registration Statement on Form S-3 Filed December 23, 2024 File No. 333-284009 Dear James E. Dentzer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cynthia T. Mazareas, Esq.

Show Raw Text
December 31, 2024
James E. Dentzer
President and Chief Executive Officer
Curis, Inc.
128 Spring Street, Building C - Suite 500
Lexington, MA 02421
Re:Curis, Inc.
Registration Statement on Form S-3
Filed December 23, 2024
File No. 333-284009
Dear James E. Dentzer:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cynthia T. Mazareas, Esq.